Literature DB >> 11786056

Electronegative electroretinogram in mucolipidosis IV.

Shan M Pradhan1, La-Ongsri Atchaneeyasakul, Binoy Appukuttan, Robert N Mixon, Trevor J McFarland, Andrea M Billingslea, David J Wilson, J Timothy Stout, Richard G Weleber.   

Abstract

OBJECTIVE: To demonstrate the progression of electroretinographic (ERG) findings in mucolipidosis IV.
METHODS: Two patients with mucolipidosis IV were examined clinically and their condition was followed up for ophthalmic manifestations of the disease. Electroretinograms were performed on both patients, and conjunctival biopsy specimens were analyzed for characteristic ultrastructural inclusion bodies using light and electron microscopy. Genomic DNA isolated from peripheral blood was screened for 2 major founder mutations in the ML4 gene using polymerase chain reaction and restriction fragment length polymorphism analyses. Haplotypes were confirmed by automated sequencing of polymerase chain reaction products.
RESULTS: In patient 1, an ERG obtained at 12 months of age showed mildly subnormal amplitude of rod-mediated and cone-mediated responses and significantly prolonged rod and cone b-wave implicit times. An ERG obtained when the patient was 6.6 years old disclosed marked progression with greater loss of b-wave than a-wave responses to rod-and-cone-mediated activity. Scotopic ERG at the highest intensity was electronegative in configuration. In patient 2, ERG showed minimal rod-mediated responses, severely subnormal cone-mediated responses, and prolonged cone b-wave implicit times. Again, electronegative configuration of the scotopic bright flash response indicated greater disturbance of b-wave generators.
CONCLUSIONS: Novel ERG findings in 2 cases of mucolipidosis IV are reported with associated clinical courses, histopathologic abnormality, and genetic studies. In both cases ERGs demonstrate an electronegative configuration, suggesting that the primary retinal disturbance in mucolipidosis IV may occur at or proximal to the photoreceptor terminals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786056     DOI: 10.1001/archopht.120.1.45

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  7 in total

Review 1.  Mucolipidosis type IV: an update.

Authors:  Kazuyo Wakabayashi; Ann Marie Gustafson; Ellen Sidransky; Ehud Goldin
Journal:  Mol Genet Metab       Date:  2011-06-16       Impact factor: 4.797

Review 2.  Clinical aspects of neuropathic lysosomal storage disorders.

Authors:  Laura Bannach Jardim; Maria Mercedes Villanueva; Carolina F Moura de Souza; Cristina B Oliveira Netto
Journal:  J Inherit Metab Dis       Date:  2010-05-21       Impact factor: 4.982

Review 3.  The role of TRPMLs in endolysosomal trafficking and function.

Authors:  Kartik Venkatachalam; Ching-On Wong; Michael X Zhu
Journal:  Cell Calcium       Date:  2014-10-28       Impact factor: 6.817

4.  Non-syndromic retinitis pigmentosa due to mutations in the mucopolysaccharidosis type IIIC gene, heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT).

Authors:  Lonneke Haer-Wigman; Hadas Newman; Rina Leibu; Nathalie M Bax; Hagit N Baris; Leah Rizel; Eyal Banin; Amir Massarweh; Susanne Roosing; Dirk J Lefeber; Marijke N Zonneveld-Vrieling; Ofer Isakov; Noam Shomron; Dror Sharon; Anneke I Den Hollander; Carel B Hoyng; Frans P M Cremers; Tamar Ben-Yosef
Journal:  Hum Mol Genet       Date:  2015-04-09       Impact factor: 6.150

Review 5.  Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV-A Review and Case Series.

Authors:  Aleksandra Jezela-Stanek; Elżbieta Ciara; Karolina M Stepien
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

6.  Cross-sectional Observations on the Natural History of Mucolipidosis Type IV.

Authors:  Albert L Misko; Levi B Wood; Madeline DeBono; Rebecca Oberman; Annick Raas-Rothschild; Yulia Grishchuk; Florian Eichler
Journal:  Neurol Genet       Date:  2022-03-10

7.  Negative ERGs in mucopolysaccharidoses (MPS) Hurler-Scheie (I-H/S) and Hurler (I-H)-syndromes.

Authors:  D Tzetzi; R Hamilton; P H Robinson; G N Dutton
Journal:  Doc Ophthalmol       Date:  2007-02-16       Impact factor: 1.854

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.